Development of a drug-response modeling framework to identify cell line derived translational biomarkers that can predict treatment outcome to Erlotinib or Sorafenib

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Li, Bin ^a   Shin, Hyunjin ^a   Gulbekyan, Georgy ^b   Pustovalova, Olga ^b   Nikolsky, Yuri ^b   Hope, Andrew ^b   Bessarabova, Marina ^b   Schu, Matthew ^a   Kolpakova Hart, Elona ^b   Merberg, David ^a   Dorner, Andrew ^a   Trepicchio, William L ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b THOMSON REUTERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ERLOTINIB; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PHARMACOLOGICAL BIOMARKER;

ARTICLE; CANCER CELL LINE; CANCER RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IC50; LUNG CANCER; NON SMALL CELL LUNG CANCER; PARTIAL LEAST SQUARES REGRESSION; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; ANALOGS AND DERIVATIVES; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; MORTALITY; NEOPLASMS; PATHOLOGY; PRECLINICAL STUDY; SIGNAL TRANSDUCTION; STATISTICAL MODEL; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MODELS, STATISTICAL; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84938909356     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130700     Document Type: Article

References (50)

1. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, et al. CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set. Cancer Res. 2012; 72(14):3499-511. Epub 2012/07/18. doi: 0008-5472.CAN-12-1370 [pii] doi: 10.1158/0008-5472.CAN-12-1370 PMID: 22802077; PubMed Central PMCID: PMC3399763.
2. Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther. 2006; 5(4):853-67. Epub 2006/05/02. doi: 5/4/853 [pii] doi: 10.1158/1535-7163.MCT-05-0155 PMID: 16648555; PubMed Central PMCID: PMC2733874.
3. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A. 2007; 104(32):13086-91. Epub 2007/08/02. doi: 0610292104 [pii] doi: 10.1073/pnas.0610292104 PMID: 17666531; PubMed Central PMCID: PMC1941805.
4. Shoemaker RH, Monks A, Alley MC, Scudiero DA, Fine DL, McLemore TL, et al. Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res. 1988; 276:265-86. Epub 1988/01/01. PMID: 3051021.
5. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr., Kohn KW, et al. An information-intensive approach to the molecular pharmacology of cancer. Science. 1997; 275(5298):343-9. Epub 1997/01/17. PMID: 8994024.
6. Lee JK, Bussey KJ, Gwadry FG, Reinhold W, Riddick G, Pelletier SL, et al. Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol. 2003; 4(12):R82. Epub 2003/12/09. doi: 10.1186/gb-2003-4-12-r82 gb-2003-4-12-r82 [pii] PMID: 14659019; PubMed Central PMCID: PMC329421.
7. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A. 2003; 100(24):14229-34. Epub 2003/11/19. doi: 10.1073/pnas.2331323100 2331323100 [pii] PMID: 14623978; PubMed Central PMCID: PMC283574.
8. Reinhold WC, Reimers MA, Maunakea AK, Kim S, Lababidi S, Scherf U, et al. Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Mol Cancer Ther. 2007; 6 (2):391-403. Epub 2007/02/03. doi: 1535-7163.MCT-06-0609 [pii] doi: 10.1158/1535-7163.MCT-06-0609 PMID: 17272646.
9. Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther. 2007; 6(5):1483-91. Epub 2007/05/08. doi: 1535-7163. MCT-07-0009 [pii] doi: 10.1158/1535-7163.MCT-07-0009 PMID: 17483436.
10. Fagan A, Culhane AC, Higgins DG. A multivariate analysis approach to the integration of proteomic and gene expression data. Proteomics. 2007; 7(13):2162-71. Epub 2007/06/06. doi: 10.1002/pmic.200600898 PMID: 17549791.
11. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther. 2006; 5(11):2606-12. Epub 2006/11/08. doi: 1535-7163.MCT-06-0433 [pii] doi: 10.1158/1535-7163.MCT-06-0433 PMID: 17088437; PubMed Central PMCID: PMC2705832.
12. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012; 483(7391):570-5. Epub 2012/03/31. doi: 10.1038/nature11005 nature11005 [pii] PMID: 22460902; PubMed Central PMCID: PMC3349233.
13. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483 (7391):603-7. Epub 2012/03/31. doi: 10.1038/nature11003 nature11003 [pii] PMID: 22460905; PubMed Central PMCID: PMC3320027.
14. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25):1999-2009. Epub 2002/12/20. doi: 10.1056/NEJMoa021967 347/25/1999 [pii] PMID: 12490681.
15. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. Epub 2004/12/14. doi: NEJMoa041588 [pii] doi: 10.1056/NEJMoa041588 PMID: 15591335.
16. Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010; 28(8):827-38. Epub 2010/08/03. doi: nbt.1665 [pii] doi: 10.1038/nbt.1665 PMID: 20676074; PubMed Central PMCID: PMC3315840.
17. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006; 108(6):2020-8. Epub 2006/05/27. doi: blood-2005-11-013458 [pii] doi: 10.1182/blood-2005-11-013458 PMID: 16728703; PubMed Central PMCID: PMC1895543.
18. Shaughnessy JD Jr., Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007; 109(6):2276-84. Epub 2006/11/16. doi: blood-2006-07-038430 [pii] doi: 10.1182/blood-2006-07-038430 PMID: 17105813.
19. Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr., Bryant B. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood. 2008; 111(2):968-9. Epub 2008/01/10. doi: 111/2/968 [pii] doi: 10.1182/blood-2007-10-119321 PMID: 18182586; PubMed Central PMCID: PMC2200846.
20. Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol. 2008; 26(29):4798-805. Epub 2008/07/02. doi: 10.1200/JCO.2007.13.8545 JCO.2007.13.8545 [pii] PMID: 18591550.
21. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007; 109 (8):3177-88. Epub 2006/12/23. doi: blood-2006-09-044974 [pii] doi: 10.1182/blood-2006-09-044974 PMID: 17185464.
22. Lazar C, Meganck S, Taminau J, Steenhoff D, Coletta A, Molter C, et al. Batch effect removal methods for microarray gene expression data integration: a survey. Briefings in bioinformatics. 2013; 14(4):469-90. Epub 2012/08/02. doi: 10.1093/bib/bbs037 PMID: 22851511.
23. Lazar C, Taminau J, Meganck S, Steenhoff D, Coletta A, Solis DY, et al. GENESHIFT: a nonparametric approach for integrating microarray gene expression data based on the inner product as a distance measure between the distributions of genes. IEEE/ACM transactions on computational biology and bioinformatics / IEEE, ACM. 2013; 10(2):383-92. Epub 2013/08/10. doi: 10.1109/TCBB.2013.12 PMID: 23929862.
24. Wold S, Sjostrom M, Eriksson L. PLS-regression: a basic tool of chemometrics. Chemometrics and Intelligent Laboratory Systems. 2001; 58:109-30.
25. Janes KA, Gaudet S, Albeck JG, Nielsen UB, Lauffenburger DA, Sorger PK. The response of human epithelial cells to TNF involves an inducible autocrine cascade. Cell. 2006; 124(6):1225-39. Epub 2006/03/28. doi: S0092-8674(06)00292-3 [pii] doi: 10.1016/j.cell.2006.01.041 PMID: 16564013.
26. Lindgren F, Geladi P, Wold S. The kernel algorithm for PLS. J Chemometrics. 1993; 7:45-59.
27. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr., Tsao A, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011; 1(1):44-53. Epub 2012/05/16. doi: 2159-8274. CD-10-0010 [pii] doi: 10.1158/2159-8274.CD-10-0010 PMID: 22586319.
28. Benjamini Y, Hochberg Y. The control of the false discovery rate in multiple testing under dependency. Annals of Statistics. 1995; 29:1165-88.
29. Chun H, Keles S. Expression quantitative trait loci mapping with multivariate sparse partial least squares regression. Genetics. 2009; 182(1):79-90. Epub 2009/03/10. doi: 10.1534/genetics.109.100362 PMID: 19270271; PubMed Central PMCID: PMC2674843.
30. Chun H, Keles S. Sparse partial least squares regression for simultaneous dimension reduction and variable selection. Journal of the Royal Statistical Society Series B, Statistical methodology. 2010; 72 (1):3-25. Epub 2010/01/29. doi: 10.1111/j.1467-9868.2009.00723.x PMID: 20107611; PubMed Central PMCID: PMC2810828.
31. Le Cao KA, Boitard S, Besse P. Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. BMC Bioinformatics. 2011; 12:253. Epub 2011/06/23. doi: 1471-2105-12-253 [pii] doi: 10.1186/1471-2105-12-253 PMID: 21693065; PubMed Central PMCID: PMC3133555.
32. Le Cao KA, Martin PG, Robert-Granie C, Besse P. Sparse canonical methods for biological data integration: application to a cross-platform study. BMC Bioinformatics. 2009; 10:34. Epub 2009/01/28. doi: 10.1186/1471-2105-10-34 PMID: 19171069; PubMed Central PMCID: PMC2640358.
33. Witten DM, Tibshirani RJ. Extensions of sparse canonical correlation analysis with applications to genomic data. Statistical applications in genetics and molecular biology. 2009; 8:Article28. Epub 2009/07/04. doi: 10.2202/1544-6115.1470 PMID: 19572827; PubMed Central PMCID: PMC2861323.
34. Demmel J, Kahan W. Accurate Singular-Values of Bidiagonal Matrices. Siam J Sci Stat Comp. 1990; 11(5):873-912. doi: 10.1137/0911052 WOS:A1990DU98400005.
35. Bessarabova M, Ishkin A, JeBailey L, Nikolskaya T, Nikolsky Y. Knowledge-based analysis of proteomics data. BMC Bioinformatics. 2012; 13(Suppl 16):S13 doi: 10.1186/1471-2105-13-S16-S13 PMID: 23176192
36. Perakslis ED, Van Dam J, Szalma S. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development. Clin Pharmacol Ther. 2010; 87(5):614-6. Epub 2010/04/09. doi: 10.1038/clpt.2010.21 clpt201021 [pii] PMID: 20376001.
37. McCall MN, Irizarry RA. Thawing Frozen Robust Multi-array Analysis (fRMA). BMC Bioinformatics. 2011; 12:369. Epub 2011/09/20. doi: 10.1186/1471-2105-12-369 1471-2105-12-369 [pii] PMID: 21923903; PubMed Central PMCID: PMC3180392.
38. Virtanen C, Ishikawa Y, Honjoh D, Kimura M, Shimane M, Miyoshi T, et al. Integrated classification of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci U S A. 2002; 99(19):12357-62. doi: 10.1073/pnas.192240599 PMID: 12218176; PubMed Central PMCID: PMC129449.
39. Carlson MW, Iyer VR, Marcotte EM. Quantitative gene expression assessment identifies appropriate cell line models for individual cervical cancer pathways. BMC genomics. 2007; 8:117. doi: 10.1186/1471-2164-8-117 PMID: 17493265; PubMed Central PMCID: PMC1878486.
40. Blumenschein GR Jr., Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, et al. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013; 19 (24):6967-75. Epub 2013/10/30. doi: 10.1158/1078-0432.CCR-12-1818 1078-0432.CCR-12-1818 [pii] PMID: 24166906; PubMed Central PMCID: PMC3905243.
41. Costello JC, Heiser LM, Georgii E, Gonen M, Menden MP, Wang NJ, et al. A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol. 2014; 32(12):1202-12. Epub 2014/06/02. doi: 10.1038/nbt.2877 PMID: 24880487.
42. Bar J, Onn A. Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors. Clinical lung cancer. 2012; 13(4):267-79. doi: 10.1016/j.cllc.2011.09.001 PMID: 22154113.
43. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nature reviews Clinical oncology. 2010; 7(9):493-507. doi: 10.1038/nrclinonc.2010.97 PMID: 20551942; PubMed Central PMCID: PMC2929287.
44. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003; 19(2):185-93. Epub 2003/01/23. PMID: 12538238.
45. Luo J, Schumacher M, Scherer A, Sanoudou D, Megherbi D, Davison T, et al. A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J. 2010; 10(4):278-91. Epub 2010/08/03. doi: tpj201057 [pii] doi: 10.1038/tpj.2010.57 PMID: 20676067; PubMed Central PMCID: PMC2920074.
46. McCall MN, Bolstad BM, Irizarry RA. Frozen robust multiarray analysis (fRMA). Biostatistics. 2010; 11 (2):242-53. doi: 10.1093/biostatistics/kxp059 PMID: 20097884; PubMed Central PMCID: PMC2830579.
47. Katz S, Irizarry RA, Lin X, Tripputi M, Porter MW. A summarization approach for Affymetrix GeneChip data using a reference training set from a large, biologically diverse database. BMC Bioinformatics. 2006; 7:464. Epub 2006/10/25. doi: 1471-2105-7-464 [pii] doi: 10.1186/1471-2105-7-464 PMID: 17059591; PubMed Central PMCID: PMC1624855.
48. Nikolsky Y, Kirillov E, Zuev R, Rakhmatulin E, Nikolskaya T. Functional Analysis of OMICs Data and Small Molecule Compounds in an Integrated "Knowledge-Based" Platform. Methods Mol Biol. 2009; 563:177-96. doi: 10.1007/978-1-60761-175-2-10 WOS:000269615300010. PMID: 19597786
49. Vellaichamy A, Dezso Z, JeBailey L, Chinnaiyan AM, Sreekumar A, Nesvizhskii AI, et al. "Topological Significance" Analysis of Gene Expression and Proteomic Profiles from Prostate Cancer Cells Reveals Key Mechanisms of Androgen Response. Plos One. 2010; 5(6). doi: ARTN e10936 doi: 10.1371/journal.pone.0010936 WOS:000278318700010.
50. Dezso Z, Nikolsky Y, Nikolskaya T, Miller J, Cherba D, Webb C, et al. Identifying disease-specific genes based on their topological significance in protein networks. Bmc Syst Biol. 2009; 3. doi: Artn 36. doi: 10.1186/1752-0509-3-36 WOS:000266001700001.